Meta-analysis · people

Cerebrolysin: better NIHSS scores after stroke across nine trials

Checked against the paper Meta-analysisPublished by PepVault

The takeaway

Pooled across nine placebo-controlled trials, Cerebrolysin started within 72 h of an ischemic stroke was linked to better early neurological scores, with safety similar to placebo.

Kind
Meta-analysis
Studied in
People
Number studied
1879
Published
2018
Journal
Neurol Sci

What they tested

Does Cerebrolysin, started soon after an ischemic stroke, improve overall neurological recovery in the early weeks compared with placebo?

How the study was done

A meta-analysis pooling nine randomized, double-blind, placebo-controlled trials in people with ischemic stroke, with 1879 patients in the main analysis. Patients got 30-50 ml of Cerebrolysin or placebo, a dummy treatment, once a day for 10-21 days, starting within 72 h of the stroke, and five trials contributed individual patient data while four contributed aggregate data.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking cerebrolysin? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

On the NIHSS (National Institutes of Health Stroke Scale, a score of stroke-related deficits) at day 30 (or 21), Cerebrolysin did better than placebo, with a Mann-Whitney effect size of 0.60 (P < 0.0001, N = 1879). The number needed to treat for a clinically relevant NIHSS change was 7.7 (95% CI 5.2 to 15.0), meaning how many patients needed treatment for one extra to improve. In 314 patients with moderate to severe stroke, the modified Rankin Scale, a measure of disability, at day 90 also favored Cerebrolysin (MW 0.61, 95% CI 0.52 to 0.69, P = 0.0118). Safety was comparable to placebo.

What it doesn’t show

The main result covers early recovery, up to about a month; the 90-day disability result comes from a smaller group of 314 patients with moderate to severe stroke. Four of the pooled trials entered the analysis as aggregate data rather than individual patient data.

The paper

Bornstein et al. Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials. Neurol Sci. 2018.

The compound

More studies on Cerebrolysin

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking cerebrolysin? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo